FilingReader Intelligence
Marksans Pharma reports mixed Q1 results despite revenue growth
August 19, 2025 at 05:29 AM UTC•By FilingReader AI
Marksans Pharma reported Q1 FY26 revenue of INR620 crores, up 5% year-on-year. US and North America revenue jumped 30.6% to INR327.6 crores from new product launches.
However, profit after tax plunged 34.7% to INR58.2 crores due to higher employee expenses and a INR10.48 crores credit loss provision. UK market revenue declined 20% from seasonality and pricing erosion.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:MARKSANS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Marksans Pharma publishes news
Free account required • Unsubscribe anytime